Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model.
Follicular lymphomas (FLs) account for 35-40% of all adult lymphomas. Treatment typically involves chemotherapy combined with the anti-CD20 monoclonal antibody (MAb) rituximab (RTX). The development of the type II anti-CD20 MAb obinutuzumab (GA101) aims to further improve treatment. Here, using FL cells we show that RTX and GA101 display a similar activity on RL cells cultured in 2D. However, 2D culture cannot mimic tumor spatial organization and conventional 2D models may not reflect the effects of antibodies as they occur in vivo. Thus, we created a non-Hodgkin's lymphoma (NHL) 3D culture system, termed multicellular aggregates of lymphoma cells (MALC), and used it to compare RTX and GA101 activity. Our results show that both antibodies display greater activity towards FL cells in 3D culture compared with 2D culture. Moreover, we observed that in the 3D model GA101 was more effective than RTX both in inhibiting MALC growth through induction of (lysosomal) cell death and senescence and in inhibiting intracellular signaling pathways, such as mammalian target of rapamycin, Akt, PLCgamma (Phospholipase C gamma) and Syk. Altogether, our study demonstrates that spatial organization strongly influences the response to antibody treatment, supporting the use of 3D models for the testing of therapeutic agents in NHL.
1] INSERM UMR1037-Centre de Recherche en Cancérologie de Toulouse, Toulouse, France [2] Université Toulouse III Paul-Sabatier, Toulouse, France [3] ERL 5294 CNRS, BP3028, Hôpital Purpan, Toulouse, France [4] Institut Carnot Lymphome-CALYM, Toulouse, France [5] Laboratoire d'Excellence Toulouse Cancer-TOUCAN, Toulouse, France [6] Institut de Recherche Roche, Boulogne Billancourt, France.
E
E
Decaup
C
C
Jean
C
C
Laurent
P
P
Gravelle
S
S
Fruchon
F
F
Capilla
A
A
Marrot
T
T
Al Saati
F-X
FX
Frenois
G
G
Laurent
C
C
Klein
N
N
Varoqueaux
A
A
Savina
J-J
JJ
Fournié
C
C
Bezombes